Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + bortezomib + dexamethasone for newly diagnosed multiple myeloma with renal impairment
ChiCTR2500103348Phase 3Not yet recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of daratumumab, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Beijing Chaoyang Hospital. Primary endpoints: Overall renal response rate at 3 months (>= MR), Overall response rate and 3 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
daratumumabbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500103348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103348.